Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.63 |
| ▸ | CDC25A | P30304 | 4/20 | 0.62 |
| ▸ | POLA1 | P09884 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | VDR | P11473 | 2/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.57 |
| ▸ | HPSE | Q9Y251 | 9/20 | 0.57 |
| ▸ | FGF1 | P05230 | 7/20 | 0.57 |
| ▸ | FGF2 | P09038 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11109512 | 1.00 | ST6GAL1 (0.63) | ST6GAL1CDC25APOLA1CYP2D6CYP2C19 | |
| SCHEMBL3135366 | 1.00 | ST6GAL1 (0.63) | ST6GAL1CDC25APOLA1CYP2D6CYP2C19 | |
| SCHEMBL23628425 | 1.00 | ST6GAL1 (0.63) | ST6GAL1CDC25APOLA1CYP2D6CYP2C19 | |
| SCHEMBL875405 | 0.91 | CDC25A (0.62) | ST6GAL1CDC25APOLA1CYP2D6CYP2C19 | |
| SCHEMBL11458228 | 0.90 | CYP2D6 (0.53) | ST6GAL1CDC25APOLA1CYP2D6CYP2C19 | |
| SCHEMBL19253281 | 0.89 | GRIN1 (0.64) | ST6GAL1VDRABCC4 | |
| SCHEMBL19253282 | 0.89 | GRIN1 (0.64) | ST6GAL1VDRABCC4 | |
| SCHEMBL23865994 | 0.89 | ST6GAL1 (0.59) | ST6GAL1VDRABCC4 | |
| SCHEMBL8902307 | 0.86 | ST6GAL1 (0.82) | ST6GAL1CDC25APOLA1CYP2D6CYP2C19 | |
| SCHEMBL8902302 | 0.86 | ST6GAL1 (0.82) | ST6GAL1CDC25APOLA1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2625190-B1 | DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN ANTIPARASITIC, ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTION | UNIV JUSTUS LIEBIG GIESSEN (DE) | 2021-07-14 | — | — | EP | disclosed |
| US-9382288-B2 | Derivatives of steroid benzylamines, having an antiparasitic antibacterial, antimycotic and/or antiviral action | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2016-07-05 | — | — | US | disclosed |
| US-9180132-B2 | Antimicrobial cationic steroids and methods of use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-11-10 | — | — | US | disclosed |
| US-9056048-B2 | Synthesis and use of cationic steroids for anti-inflammatory drug therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130266645-A1 | DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN ANTIPARASITIC ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTION | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2013-10-10 | — | — | US | disclosed |
| US-20130137668-A1 | Antimicrobial Cationic Steroids and Methods of Use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2010062562-A1 | SYNTHESIS AND USE OF CATIONIC STEROIDS FOR ANTI-INFLAMMATORY DRUG THERAPY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20090124591-A1 | Synthesis and Use of Cationic Steroids for Anti-Inflammatory Drug Therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2009-05-14 | — | — | US | disclosed |
| US-7442386-B2 | Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1424998-A4 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | UNIV PENNSYLVANIA (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050069577-A1 | Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies | TRUSTEES OF UNIVERSITY OF PENNSYLVANIA | 2005-03-31 | — | — | US | disclosed |
| EP-1424998-A1 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | The Trustees of The University of Pennsylvania (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003015757-A1 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266645-A1 | DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN ANTIPARASITIC ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTION | HSD17B7, CYP21A2, CYP17A1 | ST6GAL1 739/4885CDC25A 1196/4885POLA1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.